Introduction
©1998 International Medical Press 0956-3202/98/$17.00 HSV-2 G) and clinical isolates (HSV-1 Itoh and Inoue) were used. Itoh and Inoue strains, supplied by K Inoue (Osaka University, Japan) were isolated from a patient with keratitis. The Inoue strain is resistant to ACV. The A4-3 strain, also supplied by K Inoue, is an ACV-resistant mutant derived from the KOS strain. Inoue and A4-3 strains were thymidine kinase-defective mutants of HSV-1. All strains were propagated in MRC-5 cells and stored at -80°C until use. Antiviral assay by the MTT method MRC-5 cells were seeded into flat-bottomed, 96-well microtitre trays (Falcon) at 1.5×10 4 cells/well and incubated at 37°C in 5% CO 2 . When the cell cultures were confluent, the growth medium was withdrawn. Each well was incubated with 100 µl of virus suspension (25 TCID 50 /200 µl) and 100 µl of test compound, then incubated for 6 to 7 days without a change of medium at 37°C in 5% CO 2 . After complete destruction of virus-infected cells, 20 µl of MTT solution (7.5 mg/ml in PBS) was added to each well of the microtitre tray. The tray was then incubated at 37°C for 24 h. Approximately 150 µl of the medium was removed from each well without disturbing the cells and 100 µl of acidified isopropanol (2 ml of concentrated HCl per 500 ml of isopropanol) containing 10% (v/v) Triton X-100 was added to each well to dissolve the formazan crystals. The absorbance of the wells was read in a computer-controlled microplate reader (Model 3550; Bio-Rad) at two different wavelengths (540 and 690 nm). The 50% cytotoxicity concentration (CC 50 ) of the test compound was defined as the concentration that reduced the absorbance of mock-infected cells to 50% of that of the controls. The 50% antiviral effective concentration (EC 50 ) was expressed as the concentration that achieved 50% protection of virus-infected cells from the HSV-induced destruction. The percentage protection was calculated by the following formula:
where (A T )HSV is the absorbance of the test sample, (A C )HSV is the absorbance of the virus-infected control (no compound) and (A C )MOCK is the absorbance of the mock-infected control. The ratio of (A C )HSV to (A C )MOCK is expressed as a percentage of control. The 
Virus yield studies
MRC-5 cell monolayers in 96-well microtitre trays were infected with HSV-1 or HSV-2 at 25 TCID 50 /well and test compounds were added. Each plate was frozen at -80°C on 1, 2 and 4 days post-infection. Intracellular virus and supernatant virus were harvested by thawing, then pooled together. The virus titre was determined using MRC-5 cells.
Results

Antiviral activity against HSV-1 and HSV-2 measured by MTT assay
The formulae of podophyllotoxin derivatives tested in this study are shown in Fig. 1 . Table 1 summarizes the inhibitory effects of six podophyllotoxin derivatives on HSV KOS and G strains in MRC-5 cells. Deoxypodophyllotoxin (RD4-6266) and podophyllotoxin (RD4-6269) were found to be potent and selective inhibitors of HSV replication. EC 50 values of RD4-6266 and RD4-6269 against KOS and G strains were superior to those of ACV. In contrast, the substitution of hydrogen at the 5-position by a methoxy group (RD4-6267) mildly decreased the anti-HSV-1 and -2 activities of RD4-6266. The efficacy of RD4-6267 against KOS and G strains, however, was comparable to that of ACV. Moreover, the inhibitory effects of demethylene-deoxypodophyllotoxin (RD4-6283) were lower than those of deoxypodophyllotoxin. It is assumed that the methylenedioxy ring A has an influence on HSV replication. In contrast, podorhizol (RD4-6277) and 5′-methoxypodorhizol (RD4-6276) failed to inhibit KOS and G strains. These results suggest that ring C (the bond between carbons 4 and 5) is important for the inhibitory effect against HSV replication.
Antiviral activity against clinical isolates and ACV-resistant viruses
It is clinically important to evaluate antiviral activity against a variety of HSV strains. Accordingly, anti-HSV activity against clinical isolates of HSV-1 (Itoh and Inoue strains) and against ACV-resistant strains (Inoue and A4-3) was examined using the MTT method. Table 2 shows the antiviral activities of four podophyllotoxin derivatives that had been found to inhibit markedly the replication of the KOS and G strains. ACV showed antiviral activity against the Itoh strain, while Inoue and A4-3 strains were propagated in the presence of ACV. The four podophyllotoxin derivatives also inhibited the replication of the clinical †The Itoh strain was isolated from a patient with keratitis. ‡The Inoue strain was isolated from a patient with keratitis. §The A4-3 strain is an ACV-resistant mutant derived from KOS strain.
Figure 2. Effect of podophyllotoxin (RD4-6266) on production of infectious virus particles
Control (untreated) (•); 0.02 µg/ml RD4-6266 (❏); 0.1 µg/ml ACV (■). Antiviral assays were carried out using HSV-1 KOS strain and HSV-2 G strain in MRC-5 cells. Virus input was 25 TCID 50 /well. 
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Time post-infection (days) strains at a low concentration. Although ACV was not effective against the Inoue and A4-3 strains, the podophyllotoxin derivatives inhibited the replication of ACV-resistant strains at a concentration as low as that which produced inhibition of the KOS and G strains. We tested the antiviral activity of the derivatives against other viruses. They did not inhibit the replication of respiratory syncytial virus, influenza A virus or human cytomegalovirus (HCMV; data not shown).
Inhibition of virus yield
To observe the inhibition of virus growth, virus yield in cell cultures infected with 25 TCID 50 of the KOS or G strain was monitored on day 1, 2 and 4 after virus infection. Fig.  2 shows the production of infectious virus particles in cells treated with RD4-6266 and ACV. On day 1 post-infection, there was no difference in the production of infectious virus particles in untreated HSV-infected cells and infected cells treated with RD4-6266 or ACV. On day 2, both RD4-6266 and ACV inhibited production of virus particles. The order of decreasing effectiveness for treatment on day 4 was: RD4-6266 (0.02 µg/ml) > ACV (0.1 µg/ml) > untreated control against the KOS strain; and ACV (0.1 µg/ml) = RD4-6266 (0.02 µg/ml) > untreated control against the G strain. These results indicate that the inhibition of formazan formation in the MTT assay may be related to virus growth in the cells.
Discussion
In the present study, we observed antiviral activity of podophyllotoxin derivatives against HSV-1, HSV-2 and ACV-resistant HSV strains. Podophyllotoxin and its derivatives have considerable anti-tumour activity and thus have been well-evaluated in clinical trials. As an experimental cancer chemotherapy agent, podophyllotoxin has been administered intravenously to patients at doses of 0.5 to 1.0 mg/kg/day. With such therapy, bone marrow and gastrointestinal toxicities were noted at an average cumulative dose of 6 mg/kg (Savel, 1964) . Studies have reported that topical podophyllotoxin (podofilox) application can be used safely and effectively for home treatment, with acceptable side-effects that are local and temporary (Strauss et al., 1996; Stone, 1995; Bonnez et al., 1994) . Podofilox was recently approved by the US Food and Drug Administration (Stone, 1995) . Hansen et al. (1993) reported that neither podophyllotoxin nor its congeners inhibited HSV-2, human immunodeficency virus (HIV) or HCMV infections at the highest dose not toxic to target cells. San Feliciano et al. (1993) also reported that none of these tested compounds had antiviral effects on HSV-1 (in CV-1 cells) after incubation for 2 days. However, Gordaliza et al. (1994) proved that deoxypodophyllotoxin was the most potent compound against HSV-1 replication (IC 50 0.03 µM) when an antiviral assay was performed on HSV-1 (in CV-1 cells) after 1 day incubation with some podophyllotoxin derivatives. One notable difference between the two experiments was the incubation time.
Several reports showed antiviral activities of DNA topoisomerase inhibitors. The anti-eukaryotic topoisomerase drugs camptothecin and etoposide were reported to interfere with the replication of simian virus 40 (Maschera et al., 1993) . Podophyllotoxin derivatives such as etoposide (VP-16) and teniposide (VM-26) are known to be potent inhibitors of DNA topoisomerase II. VM-26 selectively interferes with the relegation step of the topoisomerase II-DNA reaction (Chen et al., 1984) . The interaction between host type II DNA topoisomerases and viral DNA was examined during lytic HSV-1 infection (Ebert et al., 1990 (Ebert et al., , 1994 . Endogenous host topoisomerase II acts upon HSV-1 DNA in infected cells, and p170, a 170 kDa form of topoisomerase II, is the primary agent that induces dsDNA cleavage of progeny viral DNA molecules. Recently, Hammarsten et al. (1996) showed that ICRF-193, which is a specific cellular topoisomerase II inhibitor, dramatically inhibited the synthesis of HSV DNA, resulting in a decreased yield of infectious virus. Moreover, it has been reported that VP-16-213, a semi-synthetic derivative of podophyllotoxin, affects HSV-2 replication (Nishiyama et al., 1987) . Deoxypodophyllotoxin had a slightly lower inhibitory effect on DNA topoisomerase II (IC 50 186.5 µM) than did VP-16 (IC 50 59.2 µM; Terada et al., 1992) . On the other hand, it was reported that ring Caromatized podophyllotoxin analogues did not inhibit DNA topoisomerase II at 200 µM (Beers et al., 1988) .
Podophyllotoxin has a number of biological properties that can explain the therapeutic effect observed in the treatment of warts; for example, the drug binds to tubulin at a site close to the colchicine binding site and prevents polymerization of tubulin into microtubules (Manso-Martinez, 1982; Loike & Horowitz, 1976) . Moreover, methylenedioxy rings A and C are clearly important for antiviral activity against HSV-1 and HSV-2. 6,7-Demethylene compounds of deoxypodophyllotoxin, in which ring A was eliminated, did not interfere with tubulin polymerization (Terada et al., 1992) . This result indicates that an intact 6,7-methylenedioxy group of deoxypodophyllotoxin is necessary to inhibit tubulin polymerase. It is reported that ring C and D of podophyllotoxin and its congeners are involved in their reaction with the podophyllotoxin-binding site in tubulin (Loike et al., 1978) . At 50 µM, neither the podophyllotoxin derivative in which ring D is absent, nor the podophyllotoxin in which ring C is eliminated and a modified lactone ring is free to rotate, showed any effect on the assembly of microtubules.
In conclusion, podophyllotoxin and its derivatives inhibited the replication of HSV-1 and HSV-2 using an MTT assay and a virus yield test. They were also effective against clinical isolates (Itoh and Inoue strains) and ACVresistant strains (Inoue and A4-3 strains). Patient-applied podophyllotoxin is widely available and well-received by patients and physicians as a first-line therapy for external genital warts (Beutner & von Krogh, 1990) . It is not clear, however, whether podophyllotoxin derivatives can be used as an antiviral agent with a significant therapeutic ratio in patients infected with HSV because the compounds are highly toxic to man. On the other hand, podophyllotoxin derivatives may be a useful topical treatment for HSV, especially because its mechanism of action differs from that of currently used antiviral agents. Evidently, further studies in vivo are required to select the best candidate podophyllotoxin derivatives for clinical trials.
